The effectiveness of supplemental and replacement blended cognitive behavioral therapy for internalizing disorders: a meta-analysis.

Cogn Behav TherNov 6, 2025 (epub)
Clinical ResearchPsychiatry

Sara L M Velthuizen, Miranda C Lutz, Esther van den Bos et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined blended cognitive behavioral therapy (bCBT), which combines face-to-face and online therapy, for internalizing disorders including anxiety and depression. It synthesized comparisons with treatment as usual and pre-to-post treatment changes. Across 19 studies (N = 2749), supplementary bCBT had a significantly greater treatment effect than usual care (Cohen's d = 0.41, 95% CI [0.24, 0.59]); replacement bCBT was comparable to usual care (d = -0.01, 95% CI [-0.18, 0.17]). A second analysis of 32 studies (N = 1895) found significant improvement with bCBT overall.

Key findings

  • Supplementary bCBT outperformed treatment as usual (Cohen's d = 0.41, 95% CI [0.24, 0.59]).
  • Replacement bCBT was on par with treatment as usual (d = -0.01, 95% CI [-0.18, 0.17]).
  • Across 32 studies (N = 1895), pre-to-post improvement with bCBT was significant (Morris's D = 1.12, 95% CI [0.92, 1.33]), irrespective of blended method or therapist contact.

Why it matters

The findings distinguish two ways of integrating online therapy with in-clinic care: adding online components was associated with better outcomes than usual care, whereas replacing some face-to-face sessions did not show an advantage over usual care. This distinction may help frame evaluation of blended treatment models for anxiety and depression, while the overall improvement finding supports continued consideration of bCBT.

Source

Published in Cogn Behav Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.